Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.

Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC) harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found in several human cancer subtypes. In dogs, this mutation provides both a powerful diagnostic marker and a potential therapeut...

Full description

Bibliographic Details
Main Authors: Rachael Thomas, Claire A Wiley, Emma L Droste, James Robertson, Brant A Inman, Matthew Breen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-04-01
Series:PLoS Genetics
Online Access:https://doi.org/10.1371/journal.pgen.1010575
_version_ 1797736635529428992
author Rachael Thomas
Claire A Wiley
Emma L Droste
James Robertson
Brant A Inman
Matthew Breen
author_facet Rachael Thomas
Claire A Wiley
Emma L Droste
James Robertson
Brant A Inman
Matthew Breen
author_sort Rachael Thomas
collection DOAJ
description Molecular profiling studies have shown that 85% of canine urothelial carcinomas (UC) harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found in several human cancer subtypes. In dogs, this mutation provides both a powerful diagnostic marker and a potential therapeutic target; however, due to their relative infrequency, the remaining 15% of cases remain understudied at the molecular level. We performed whole exome sequencing analysis of 28 canine urine sediments exhibiting the characteristic DNA copy number signatures of canine UC, in which the BRAF V595E mutation was undetected (UDV595E specimens). Among these we identified 13 specimens (46%) harboring short in-frame deletions within either BRAF exon 12 (7/28 cases) or MAP2K1 exons 2 or 3 (6/28 cases). Orthologous variants occur in several human cancer subtypes and confer structural changes to the protein product that are predictive of response to different classes of small molecule MAPK pathway inhibitors. DNA damage response and repair genes, and chromatin modifiers were also recurrently mutated in UDV595E specimens, as were genes that are positive predictors of immunotherapy response in human cancers. Our findings suggest that short in-frame deletions within BRAF exon 12 and MAP2K1 exons 2 and 3 in UDV595E cases are alternative MAPK-pathway activating events that may have significant therapeutic implications for selecting first-line treatment for canine UC. We developed a simple, cost-effective capillary electrophoresis genotyping assay for detection of these deletions in parallel with the BRAF V595E mutation. The identification of these deletion events in dogs offers a compelling cross-species platform in which to study the relationship between somatic alteration, protein conformation, and therapeutic sensitivity.
first_indexed 2024-03-12T13:16:47Z
format Article
id doaj.art-b8fc0a9441674eadaf73b618fbfcb93f
institution Directory Open Access Journal
issn 1553-7390
1553-7404
language English
last_indexed 2024-03-12T13:16:47Z
publishDate 2023-04-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Genetics
spelling doaj.art-b8fc0a9441674eadaf73b618fbfcb93f2023-08-27T05:31:42ZengPublic Library of Science (PLoS)PLoS Genetics1553-73901553-74042023-04-01194e101057510.1371/journal.pgen.1010575Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.Rachael ThomasClaire A WileyEmma L DrosteJames RobertsonBrant A InmanMatthew BreenMolecular profiling studies have shown that 85% of canine urothelial carcinomas (UC) harbor an activating BRAF V595E mutation, which is orthologous to the V600E variant found in several human cancer subtypes. In dogs, this mutation provides both a powerful diagnostic marker and a potential therapeutic target; however, due to their relative infrequency, the remaining 15% of cases remain understudied at the molecular level. We performed whole exome sequencing analysis of 28 canine urine sediments exhibiting the characteristic DNA copy number signatures of canine UC, in which the BRAF V595E mutation was undetected (UDV595E specimens). Among these we identified 13 specimens (46%) harboring short in-frame deletions within either BRAF exon 12 (7/28 cases) or MAP2K1 exons 2 or 3 (6/28 cases). Orthologous variants occur in several human cancer subtypes and confer structural changes to the protein product that are predictive of response to different classes of small molecule MAPK pathway inhibitors. DNA damage response and repair genes, and chromatin modifiers were also recurrently mutated in UDV595E specimens, as were genes that are positive predictors of immunotherapy response in human cancers. Our findings suggest that short in-frame deletions within BRAF exon 12 and MAP2K1 exons 2 and 3 in UDV595E cases are alternative MAPK-pathway activating events that may have significant therapeutic implications for selecting first-line treatment for canine UC. We developed a simple, cost-effective capillary electrophoresis genotyping assay for detection of these deletions in parallel with the BRAF V595E mutation. The identification of these deletion events in dogs offers a compelling cross-species platform in which to study the relationship between somatic alteration, protein conformation, and therapeutic sensitivity.https://doi.org/10.1371/journal.pgen.1010575
spellingShingle Rachael Thomas
Claire A Wiley
Emma L Droste
James Robertson
Brant A Inman
Matthew Breen
Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
PLoS Genetics
title Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
title_full Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
title_fullStr Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
title_full_unstemmed Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
title_short Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
title_sort whole exome sequencing analysis of canine urothelial carcinomas without braf v595e mutation short in frame deletions in braf and map2k1 suggest alternative mechanisms for mapk pathway disruption
url https://doi.org/10.1371/journal.pgen.1010575
work_keys_str_mv AT rachaelthomas wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption
AT claireawiley wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption
AT emmaldroste wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption
AT jamesrobertson wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption
AT brantainman wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption
AT matthewbreen wholeexomesequencinganalysisofcanineurothelialcarcinomaswithoutbrafv595emutationshortinframedeletionsinbrafandmap2k1suggestalternativemechanismsformapkpathwaydisruption